There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Idexx Laboratories (IDXX – Research Report) and Sarepta Therapeutics (SRPT – Research Report) with bullish sentiments.
Idexx Laboratories (IDXX)
Stifel Nicolaus analyst Jonathan Block maintained a Buy rating on Idexx Laboratories on June 24 and set a price target of $500.00. The company’s shares closed last Friday at $361.48, close to its 52-week low of $318.50.
According to TipRanks.com, Block is a 5-star analyst with an average return of
Idexx Laboratories has an analyst consensus of Moderate Buy, with a price target consensus of $583.83.
Sarepta Therapeutics (SRPT)
In a report issued on June 23, Brian Abrahams from RBC Capital maintained a Buy rating on Sarepta Therapeutics, with a price target of $155.00. The company’s shares closed last Friday at $75.22.
According to TipRanks.com, Abrahams is a 1-star analyst with an average return of
Sarepta Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $124.14, a 76.1% upside from current levels. In a report issued on June 24, Mizuho Securities also maintained a Buy rating on the stock with a $160.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on IDXX:
- Analysts Offer Insights on Technology Companies: Alphabet Class A (GOOGL), Global Payments (GPN) and Fortinet (FTNT)
- Carnival Stock: All Aboard as Stock Sails Higher
- Weekly Market Review: Stocks Rebound as Quarter nears End
- Truist Financial Sticks to Their Buy Rating for Lendingtree (TREE)
- Non-work related loss of life